Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patisiran Phase 2 OLE in hATTR Amyloidosis
NCT01961921Phase 2Completed
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Oct 2013
- Primary completion
- Jul 2016
- Modality
- Gene Editing, Gene Silencing, Lipid-based Nanoparticles
- Countries
- 7
01
Overview
Phase 2, open-label, single-arm trial of patisiran in hereditary transthyretin amyloidosis (hATTR), sponsored by Alnylam Pharmaceuticals. Primary endpoint: Number of Participants Experiencing Adverse Events (AEs), Serious Adverse Events (SAEs) and Study Drug Discontinuation. Started Oct 2013; status: completed.
02
Drugs
patisiran
03
Conditions
hereditary transthyretin amyloidosis (hATTR)
Beyond the preview
Go deeper on NCT01961921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01961921.